Select one country in the menu below to display all the Availability and Reimbursement information of immuno-oncology medicines.The table below shows the active substance of the medicine, the indications for which it is approved by the European Medicines Agency, and whether each medicine is available and/or reimbursed. Additional comments may give you more information. You can follow the links displayed in the table to go to the sources of the information.

Austria

Information retrieved from AGES Medical Market Supervision database (in German: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx). The database provides only information on the availability of the drug in the country, with no further information about the reimbursement schemes for specific prescriptions.

Active Substance Indication Availability and Reimbursement Comments
Bevacizumab Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available, no information for indications or reimbursement
Blinatumomab Precursor Cell Lymphoblastic Leukemia-Lymphoma Available, no information for indications or reimbursement
Brentuximab vedotin Hodgkin Disease Lymphoma, Non-Hodgkin Available, no information for indications or reimbursement
Daratumumab Multiple Myeloma Available, no information for indications or reimbursement
Elotuzumab Multiple Myeloma Available, no information for indications or reimbursement
Inotuzumab ozogamicin Acute lymphoblastic leukaemia (recommended, but not approved yet) Not available (yet)
Ipilimumab Melanoma Available, no information for indications or reimbursement
Nivolumab Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Urotherial carcinoma (recommended, but not approved yet) Available, no information for indications or reimbursement
Obinutuzumab Leukemia, Lymphocytic, Chronic, B-Cell Available, no information for indications or reimbursement
Ofatumumab Leukemia, Lymphocytic, Chronic, B-Cell Available, no information for indications or reimbursement
Olaratumab Sarcoma Available, no information for indications or reimbursement
Pembrolizumab Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available, no information for indications or reimbursement
Rituximab (original, one biosimilar, soon also two more biosimilars for last indication) Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available, no information for indications or reimbursement
Talimogene laherparepvec (t-vec) Melanoma Available, no information for indications or reimbursement

DISCLAIMER1: This website is intended for informative purposes only, and it does not create any rights. The information displayed in this website has been obtained from publicly available sources and collected by the European Cancer Patient Coalition. Specific restrictions, lack of information on availability and/or reimbursement may exist, even depending on indications or doses, and may vary between countries. Medicines may also be used for indications other than those officially authorised by the European Medicines Agency, and may also be prescribed off-label, depending on the doctor's advice or hospital practice. Final reimbursement quantities and conditions may also depend on applicable insurance schemes or hospital practices. If you have been diagnosed with cancer, please always check with your doctor and healthcare provider to confirm the specific conditions applying to your situation.